Shionogi Considers Redasemtide’s Future After Mixed Phase II Readouts
Japanese company reviewing new mid-stage clinical findings for novel regeneration-inducing drug in dystrophic epidermolysis bullosa and acute ischemic stroke.
Scrip - September 11, 2026

Kyowa Kirin Encouraged By nAMD Eye Drop Results Despite Missed Endpoint
Japanese firm upbeat on other positive findings from study as it looks to progress non-invasive maintenance therapy for common eye disorder.
Scrip - September 11, 2026

Ex-US FDA Chief Counsel Mark Raza Joins Hogan Lovells Cadwalader
Raza spent more than 35 years at the FDA, including four years as chief counsel, before retiring from the agency in spring 2025.
Medtech Insight - September 10, 2026

XCath Robotics Receives FDA Breakthrough Device Designation For Endovascular Robot
XCath Robotics has received FDA breakthrough device designation for its Iris Surgical Robotic System. The product is the only endovascular robotic system under development to achieve intracranial navigation for neurointerventional treatments such as stroke and aneurysm care.
Medtech Insight - September 10, 2026

Execs On The Move: August 31–September 4, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - September 10, 2026

AI Devices Could Get Faster UK Regulation – In Exchange For Lifelong Monitoring
Independent commission asks MHRA to introduce staged authorization, continuous monitoring and tougher enforcement for AI medtech in the UK.
Medtech Insight - September 10, 2026

Smartphones Could Detect Alzheimer’s Symptoms To Improve Screening, Blood Tests
Evidence is growing for digital measures of cognitive decline including speech tracking, eye movements and spatial navigation – but pharma skepticism remains.
Medtech Insight - September 10, 2026

Don’t Miss the Call: Bad Contact Info Could Put Your Washington Lead Policy Status at Risk
Cosmetic manufacturers relying on Washington state's more flexible lead compliance options have a new reason to check their administrative housekeeping: a missed notice from Ecology could permanently close the door on their interim policy eligibility.
HBW Insight - September 11, 2026

Sandoz’s Biosimilar Revolution Sets Stage For 100 Products By 2040
At the London Stock Exchange this week, Sandoz set out plans to have 100 biosimilars in its portfolio by 2040, to double its sales between 2025 and 2035, and to invest heavily in biosimilar manufacturing to capture the benefits of vertical integration. Generics Bulletin delves into the details.
Generics Bulletin - September 10, 2026

Medicines For Europe Presses EU To Toughen Procurement Reform
Medicines for Europe has welcomed the EU’s shift toward quality-based procurement but wants tougher medicines-specific rules on tender criteria, multiple sourcing, low bids and supply resilience.
Generics Bulletin - September 10, 2026

As Radiopharma Comes Of Age, Generics Pose A New Kind Of Test
Novartis is betting that complex manufacturing and supply requirements will blunt generic erosion of Lutathera, even as Lantheus and Curium press closer to potential US competition after a sweeping patent defeat.
Generics Bulletin - September 10, 2026

Cardiovascular’s Harder Second Act
Two cardiovascular outcomes study failures could wipe $3.9bn from cardiovascular pipeline forecasts as Novartis's pelacarsen and Novo Nordisk's ziltivekimab become the latest casualties of a rising standard of care.
In Vivo - September 10, 2026

Execs On The Move: August 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - September 10, 2026